Cellular-therapy eligibility assessment for blood cancers
Check whether a specific cellular therapy is medically and operationally available for an individual blood cancer.
Chat on WhatsAppWhat the assessment considers
A haematology team must review the diagnosis, previous treatment, current disease status and overall fitness. Published research or a hospital news item does not confirm that a product is approved, available or offered to a particular patient.
Records for the assessment
Bring complete pathology and immunophenotyping reports. Also include a line-by-line treatment history with responses, relapses and complications.
Questions for the clinical team
Ask about the exact product and indication, alternatives and serious risks requiring specialist monitoring. Discuss collection or manufacturing steps, possible delays and what care would be needed if the disease changes while waiting.
Confirming care and arrangements
The institution must confirm product eligibility, its own authorised capability and whether it can accept an overseas patient. Treatment, monitoring, an appropriate companion, local stay and all fees need written confirmation; this page does not confirm a treatment place.
Records to prepare
- Complete pathology and immunophenotyping reports
- A line-by-line treatment history with responses, relapses and complications
- Recent disease assessments, organ-function results and infection history
Questions for your clinician
- Which exact product and authorised indication are being considered?
- What would make me ineligible, delay treatment or require a different plan?
This information helps you prepare for a clinical conversation. It does not establish a diagnosis, treatment eligibility or a confirmed booking. A listed hospital or clinician is not a claim of partnership. Seek local urgent care for an emergency.
Relevant hospitals and clinicians
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Prepared from public hospital, university, government and professional publications, with sources and dates below. Professional background is separate from current appointment availability; research findings are not guarantees of an individual outcome.
Shanghai government: Ruijin international medical servicesZhao Weili
Lymphoma and relapsed or refractory lymphoma
A Ruijin haematologist whose published work includes clinical and translational lymphoma research, including diffuse large B-cell lymphoma.
Xu Pengpeng
Lymphoma and diffuse large B-cell lymphoma
A Ruijin haematologist whose original publications address the clinical features, molecular characteristics and prognosis of lymphoma.